Form 4: Tango Therapeutics CFO Reports Equity Transactions

Tango Therapeutics' Chief Financial Officer, Daniella Beckman, reported the acquisition of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Summary

• Daniella Beckman, Chief Financial Officer of Tango Therapeutics, Inc. (TNGX), reported transactions involving the company's equity.
• Acquired 44,330 restricted stock units (RSUs) on February 2, 2026, with a deemed price of $0.
• These RSUs will vest over a three-year period: 33% on February 1, 2027, 33% on February 14, 2028, and 34% on February 12, 2029, contingent on continuous service.
• Sold 10,204 shares of common stock on February 3, 2026, at a weighted average price of $12.2573 per share, ranging from $11.88 to $12.875.
• Sold an additional 113 shares of common stock on February 3, 2026, at a weighted average price of $12.8971 per share, ranging from $12.88 to $12.91.
• These sales were automatic 'sell-to-cover' transactions to satisfy tax withholding obligations related to RSU vesting and were not discretionary.
• Acquired 265,980 stock options (right to buy) on February 2, 2026, with an exercise price of $11.94 and a deemed price of $0.
• These stock options will vest over a four-year period: 25% on January 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service.
• Following these transactions, Daniella Beckman beneficially owns 184,297 shares of common stock and 265,980 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The equity grants align management incentives with shareholders, while the sales are routine tax-related transactions, not discretionary selling.

Positives

• The Chief Financial Officer received a significant grant of 44,330 restricted stock units and 265,980 stock options, indicating continued alignment of management's interests with long-term shareholder value.
• The acquisition of stock options at an exercise price of $11.94 suggests a belief in future stock price appreciation above this level.

Negatives

• The sale of 10,317 shares of common stock, while for tax purposes, represents a reduction in direct beneficial ownership of common stock by a key executive.

Future Outlook

The reporting person's future equity holdings are tied to the company's performance through multi-year vesting schedules for both restricted stock units and stock options, extending through early 2029 for RSUs and early 2030 for stock options.

Industry Context

StockSavvy.ai notes that equity grants to executives, including RSUs and stock options, are standard compensation practices across the biotechnology and pharmaceutical industries. These grants are designed to align executive incentives with long-term shareholder value creation, a common strategy for retaining talent and motivating performance in R&D-intensive sectors like biotech.

Comparison to Industry Standards

• The vesting schedules for RSUs (three years) and stock options (four years) are consistent with typical long-term incentive plans observed in the biotechnology sector, similar to those at companies like Moderna or BioNTech, which often use multi-year vesting to ensure executive retention and sustained performance.
• The 'sell-to-cover' policy for tax obligations is a common mechanism used by publicly traded companies to facilitate executive equity compensation while managing tax liabilities, mirroring practices at many S&P 500 companies.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's long-term interests with shareholder value creation. The 'sell-to-cover' sales are minor and not indicative of a change in sentiment.
• Employees: The compensation structure reflects standard practices for executive incentives, potentially influencing broader compensation strategies.

Next Steps

• Vesting of 33% of RSUs on February 1, 2027.
• Vesting of 25% of stock options on January 1, 2027, with remaining options vesting monthly thereafter.
• Vesting of 33% of RSUs on February 14, 2028.
• Vesting of 34% of RSUs on February 12, 2029.

Key Dates

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, CFO, Daniella Beckman, Sell-to-Cover